Myriad Genetics, Inc. (NASDAQ:MYGN) concluded the trading at $19.47 on Friday, May 03, with a rise of 1.30% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $19.22. Considering stock’s 52-week price range provides that MYGN hit a high price of $24.21 and saw its price falling to a low level of $13.82 during that period. Over a period of past 1-month, stock came subtracting -3.71% in its value.
With its current market valuation of $1.75 billion. Analysts are in estimates of -0.1 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to 0.02 for current year with estimates of that growing to 0.23 in next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 193.51M. They suggested that in the process company could generate revenue of as low as 190.36M which could climb up to 196.32M to hit a high. The average estimate is representing an increase of 6.80% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of 826.58M in current fiscal year, which will be 9.70% more from revenue generated by the company last year.
In contrast, when we review MYGN stock’s current outlook then short term indicators are assigning it an average of Hold, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 50% Buy for it.
Digging deeper we become aware of the PEG ratio of the MYGN stock which is currently positioned at 0. It further provides that stock’s current price level is 1.02% away from its 20-day simple moving average and is -6.51% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 47.93 while volatility remained at 5.36% over the past week which changes to 3.86% when measuring it over the past month. Beta is valued at 1.94, while measure of average true range or ATR is currently at 0.83.
Having a second look at Myriad Genetics, Inc. (NASDAQ:MYGN) provides that stock’s average daily trading volume for 3 months was 649.25K. Number of outstanding shares of the stock stood at 89.90 million.
The percentage of outstanding shares held by the insiders is 4.29% while it is 102.03% for the institutional holders. Addition of 1.72% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
